All In Biotech

Drug Trial Radar · NCT06395948

A Study Evaluating APG777 in Atopic Dermatitis

A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 470 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

470

Actual

Start

Apr 29, 2024

Primary completion

Nov 2026

Study completion Jun 2028

Sponsor

Lead sponsor
Apogee Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

Conditions

  • Atopic Dermatitis

Interventions

  • APG777Drug

    APG777 subcutaneous injection

  • PlaceboDrug

    Matching placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI)Time frame: Baseline and at Week 16
  2. Part B: Proportion of participants who achieve EASI 75 at Week 16Time frame: At Week 16

Locations

94 sites in 9 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Fountain Valley, California

  • Investigational Site

    Los Angeles, California

  • Investigational Site

    San Diego, California

  • Investigational Site

    New Haven, Connecticut

  • Investigational Site

    Coral Gables, Florida

  • Investigational Site

    Jacksonville, Florida

  • Investigational Site

    Margate, Florida

  • Investigational Site

    Douglasville, Georgia

  • Investigational Site

    Chicago, Illinois

  • Investigational Site

    Skokie, Illinois

  • Investigational Site

    West Lafayette, Indiana

  • Investigational Site

    Bowling Green, Kentucky

  • Investigational Site

    Rockville, Maryland

  • Investigational Site

    Detroit, Michigan

  • Investigational Site

    Troy, Michigan

  • Investigational Site

    Portsmouth, New Hampshire

  • Investigational Site

    New York, New York

  • Investigational Site

    Wilmington, North Carolina

  • Investigational Site

    Boardman, Ohio

  • Investigational Site

    Mason, Ohio

  • Investigational Site

    Portland, Oregon

  • Investigational Site

    Pittsburgh, Pennsylvania

  • Investigational Site

    Charleston, South Carolina

  • Investigational Site

    Nashville, Tennessee

  • Investigational Site

    Dallas, Texas

  • Investigational Site

    Dallas, Texas

  • Investigational Site

    San Antonio, Texas

  • Investigational Site

    Norfolk, Virginia

  • Investigational Site

    Mill Creek, Washington

  • Investigational Site

    Calgary, Alberta, Canada

  • Investigational Site

    Calgary, Alberta, Canada

  • Investigational Site

    Edmonton, Alberta, Canada

  • Investigational Site

    Vancouver, British Columbia, Canada

  • Investigational Site

    Winnipeg, Manitoba, Canada

  • Investigational Site

    Fredericton, New Brunswick, Canada

  • Investigational Site

    Ajax, Ontario, Canada

  • Investigational Site

    Markham, Ontario, Canada

  • Investigational Site

    Mississauga, Ontario, Canada

  • Investigational Site

    Ottawa, Ontario, Canada

  • Investigational Site

    Peterborough, Ontario, Canada

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.